Ikena Oncology Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Ikena Oncology de winst en omzet met respectievelijk 2.9% en 69.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 17.4% per jaar.

Belangrijke informatie

2.9%

Groei van de winst

17.4%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.7%
Inkomstengroei	69.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	13 Sep 2024

Recente toekomstige groei-updates

Recent updates

Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Jun 01

Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Nov 10

Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Aug 15

Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

May 20

Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

Apr 29

We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Jan 06

Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

Aug 06

Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Mar 23

Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 21

Winst- en omzetgroeiprognoses

NasdaqGM:IKNA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-55	-80	N/A	3
12/31/2025	N/A	-50	-69	N/A	3
12/31/2024	N/A	-53	-64	N/A	3
6/30/2024	2	-67	-73	-73	N/A
3/31/2024	4	-70	-79	-78	N/A
12/31/2023	9	-68	-80	-80	N/A
9/30/2023	14	-63	-76	-76	N/A
6/30/2023	19	-63	-74	-73	N/A
3/31/2023	18	-66	-76	-74	N/A
12/31/2022	16	-69	-76	-74	N/A
9/30/2022	30	-52	-72	-70	N/A
6/30/2022	28	-49	-71	-71	N/A
3/31/2022	31	-41	-68	-67	N/A
12/31/2021	31	-34	-62	-60	N/A
9/30/2021	11	-63	-61	-59	N/A
6/30/2021	10	-55	-51	-49	N/A
3/31/2021	9	-47	-43	-41	N/A
12/31/2020	9	-44	-39	-38	N/A
9/30/2020	12	-23	-34	-33	N/A
12/31/2019	14	-17	48	48	N/A
12/31/2018	1	-41	-12	-12	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat IKNA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat IKNA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat IKNA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat IKNA volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat IKNA volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van IKNA naar verwachting over 3 jaar hoog zal zijn

Ikena Oncology Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates increase by 25%

Price target decreased by 17% to US$14.67

Price target increased by 13% to US$20.00

Consensus revenue estimates fall by 37%

Consensus revenue estimates decrease by 15%, EPS upgraded

Consensus revenue estimates increase by 32%

Recent updates

Ikena Oncology, Inc.(NasdaqGM:IKNA) dropped from Russell Small Cap Comp Value Index

Increases to CEO Compensation Might Be Put On Hold For Now at Ikena Oncology, Inc. (NASDAQ:IKNA)

Consensus revenue estimates increase by 25%

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.39 loss in 1Q 2023)

Ikena Oncology, Inc., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ikena Oncology, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Ikena Oncology, Inc. Announces Executive Changes

Ikena Oncology, Inc. Provides Corporate Updates

Ikena Oncology, Inc. Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial

Growth Investors: Industry Analysts Just Upgraded Their Ikena Oncology, Inc. (NASDAQ:IKNA) Revenue Forecasts By 31%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 17% to US$14.67

Price target increased by 13% to US$20.00

Consensus revenue estimates fall by 37%

Analysts Just Slashed Their Ikena Oncology, Inc. (NASDAQ:IKNA) EPS Numbers

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

Ikena Oncology, Inc. (NasdaqGM:IKNA) agreed to acquire Pionyr Immunotherapeutics Inc.

Ikena Oncology Regains Compliance with Listing Rule 5635(d)

Consensus revenue estimates decrease by 15%, EPS upgraded

Need To Know: Analysts Are Much More Bullish On Ikena Oncology, Inc. (NASDAQ:IKNA) Revenues

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 32%

Price target decreased by 7.0% to US$17.67

Will Ikena Oncology (NASDAQ:IKNA) Spend Its Cash Wisely?

Full year 2022 earnings: EPS and revenues miss analyst expectations

We Think Ikena Oncology (NASDAQ:IKNA) Needs To Drive Business Growth Carefully

Ikena Oncology, Inc. Announces Board Changes

Price target decreased to US$21.67

Ikena Oncology, Inc. Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

High number of new directors

Ikena Oncology, Inc. Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

Price target decreased to US$23.67

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth

Ikena Oncology, Inc.(NasdaqGM:IKNA) dropped from Russell 2500 Value Index

Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Ikena Oncology, Inc. Appoints Jotin Marango as Head of Corporate Development

Consensus forecasts updated

Ikena Oncology, Inc. Advances to Stage Two of the Nivolumab Combination Expansion Cohort in the Phase 1B Clinical Trial of IK-175 (NCT04200963)

Consensus revenue estimates increase by 15%

Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts

Ikena Oncology, Inc. (NASDAQ:IKNA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Full year 2021 earnings: Revenues exceed analyst expectations

Full year 2021 earnings: Revenues exceed analyst expectations

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Ikena Oncology, Inc. Appoints Francisco Olivera as the Acting Principal Accounting Officer

Is Ikena Oncology (NASDAQ:IKNA) In A Good Position To Deliver On Growth Plans?

Ikena Oncology, Inc. Announces Resignation of Douglas R. Carlson as Chief Operating Officer and Executive Vice President of Finance

Chief Business Officer exercised options to buy US$794k worth of stock.

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$2.34 loss in 3Q 2020)

We're Not Very Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Rate

Ikena Oncology (NASDAQ:IKNA) Is In A Good Position To Deliver On Growth Plans

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven